{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"description":"Compare the Oral TU-treated subjects and the Topical Axiron®-treated subjects with respect to number of subjects in the cosyntropin stimulation test substudy with a normal maximum post-stimulation (cosyntropin stimulation) cortisol level at Visit 8.","groups":[{"description":"Subjects receiving Oral TU participating in cosyntropin substudy","id":"OG000","title":"Oral TU Cosyntropin Substudy Subjects"},{"id":"OG001","title":"Axiron Cosyntropin Substudy Subjects"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Approximately 4.5 months","title":"Number of Participants With Post-stimulation Cortisol Level of >18 ug/dL at Visit 8","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Participants"}